Clindamycin Dosing for Cellulitis
For adult cellulitis, use clindamycin 300-450 mg orally three times daily for outpatient purulent cellulitis, or 600 mg IV/PO three times daily for hospitalized complicated cases, with treatment duration of 5-10 days for outpatients and 7-14 days for inpatients.
Outpatient Dosing
For purulent cellulitis (cellulitis with purulent drainage but no drainable abscess), clindamycin provides coverage against community-associated MRSA and β-hemolytic streptococci 1, 2, 1:
- Oral dose: 300-450 mg three times daily 1, 3
- Duration: 5-10 days, individualized based on clinical response 1, 2, 1
- Clindamycin is rated as A-I evidence for outpatient MRSA coverage 1
For nonpurulent cellulitis (no purulent drainage or abscess), clindamycin can be used when dual coverage for both streptococci and MRSA is desired, though β-lactams remain first-line 1, 2, 1:
- Same dosing: 300-450 mg PO three times daily 1
- Consider clindamycin if patient fails β-lactam therapy or has systemic toxicity 1
Critical Caveat on Weight-Based Dosing
Inadequate weight-based dosing (<10 mg/kg/day) is independently associated with clinical failure 4. For a 70 kg adult, this translates to at least 700 mg daily—meaning the standard 300 mg TID (900 mg/day) is appropriate, but 300 mg BID would be inadequate. For heavier patients, consider 450 mg TID to ensure adequate dosing.
Inpatient Dosing
For hospitalized patients with complicated SSTI (deeper infections, major abscesses, infected ulcers/burns):
- IV or oral: 600 mg three times daily 1, 2, 1
- Evidence grade: A-III (lower than vancomycin or linezolid which are A-I) 1
- Duration: 7-14 days, based on clinical response 1
The guidelines note that published data on clindamycin use in adults with complicated SSTI due to MRSA is limited 1, making it a less preferred option compared to vancomycin, linezolid, or daptomycin for severe hospitalized cases.
Pediatric Dosing
For hospitalized children with complicated SSTI 2, 1:
- IV: 10-13 mg/kg/dose every 6-8 hours (to deliver 40 mg/kg/day)
- Oral: 10-20 mg/kg/day in 3 divided doses 1, 3
- Only use if clindamycin resistance rate is low (<10%) and patient is stable without ongoing bacteremia 2, 1
- Transition to oral therapy if strain is susceptible 2, 1
Important Clinical Considerations
When NOT to Use Clindamycin
- Do not combine with rifampin for SSTI treatment 1
- Avoid if local clindamycin resistance >10% in hospitalized pediatric patients 2, 1
- Check for inducible clindamycin resistance (D-zone test) in macrolide-resistant staphylococci and streptococci 1
- Recent trial showed adding clindamycin to flucloxacillin provided no benefit and doubled diarrhea rates (22% vs 9%) 5
Drug Interactions
Clindamycin is metabolized by CYP3A4. When combined with rifampin (a strong CYP3A4 inducer), clindamycin clearance increases 3-fold and oral bioavailability drops dramatically (from 56% to 4-11% depending on rifampin dose) 6. Never use oral clindamycin with rifampin—if this combination is necessary, use IV clindamycin at doses ≥3600-4800 mg/day, preferably by continuous infusion 6.
Side Effect Profile
The most common adverse effect is Clostridioides difficile-associated diarrhea, which occurs more frequently with clindamycin than other oral alternatives 1. This risk is particularly elevated in elderly patients (>60 years) 7.
Renal/Hepatic Dosing
No dose adjustment needed for renal or hepatic impairment, as the elimination half-life increases only slightly 8. Hemodialysis does not remove clindamycin 8.
Prophylaxis for Recurrent Cellulitis
For patients with ≥3-4 episodes per year despite treating predisposing factors 9: